MXC.AX(MXC.AX)

$0.42—

Chart

MXC.AX(MXC.AX)

ASX

$0.42—

Chart Studio

MXC.AX(MXC.AX)

MXC.AX

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

8/3/26

MGC PHARMACEUTICALS (MXC.AX)

Monday

1:59 PM

Thesis: Recent strategic partnerships and potential regulatory tailwinds are improving market sentiment towards MGC Pharmaceuticals, suggesting a turnaround in performance.

Revenue Outlook

Metric	FY2023	FY2024E	FY2025E
Revenue	$3M	$13M	$19M
Rev. Growth	-28.4%	+284%	+46.9%
EPS	$-7.10	$-70.00	$-40.00
EPS Growth	+10.1%	-886%	+42.9%
P/E	—	—	—

★ Analysts see FY2024 revenue reaching $13M — +284% growth in a single year.

Why Revenue Could Explode

1MGC Pharmaceuticals has initiated a pivotal clinical trial for its lead product, which could secure market approval by Q4 2026, potentially increasing revenue by 150%.
2The company has secured partnerships with two major European healthcare providers to distribute its products, which could expand its market reach significantly.
3Recent regulatory changes in Australia may allow for faster approval of cannabinoid products, benefiting MGC's pipeline.
4A competitor has faced regulatory setbacks, potentially allowing MGC Pharmaceuticals to capture additional market share.
5Growing acceptance of cannabinoid-based therapies in mainstream medicine
6Expansion of the global cannabis market
7Regulatory approvals for new cannabinoid products
8Clinical trial results impacting product efficacy and safety

FY2023 Snapshot

Revenue: $3M
Rev. Growth: -28.4%
Gross Margin: 38.0%
Op. Margin: -457%
Net Margin: -615%
Net Income: $-21M
NI Growth: -2.3%
EPS: $-7.10

MXC.AX Chart

No chart data

My Notes

"We are positioned to capitalize on the evolving regulatory landscape and expand our market presence."
Moat: MGC Pharmaceuticals has a moderate moat due to its proprietary formulations and regulatory compliance, but faces significant competition.
growth - Investors seeking exposure to the emerging cannabis pharmaceutical market.
Higher interest rates could increase financing costs for R&D and operations, potentially impacting cash flow and valuation multiples.
Watch on earnings: Regulatory approval timelines for new products, Clinical trial success rates, Market share in the cannabinoid pharmaceuticals sector.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $13M to $19M as mgc pharmaceuticals has initiated a pivotal clinical trial for its lead product.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research note…

First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Metric

FY2023

FY2024E

FY2025E

P/E

—

Why Revenue Could Explode

1MGC Pharmaceuticals has initiated a pivotal clinical trial for its lead product, which could secure market approval by Q4 2026, potentially increasing revenue by 150%.

2The company has secured partnerships with two major European healthcare providers to distribute its products, which could expand its market reach significantly.

3Recent regulatory changes in Australia may allow for faster approval of cannabinoid products, benefiting MGC's pipeline.

4A competitor has faced regulatory setbacks, potentially allowing MGC Pharmaceuticals to capture additional market share.

5Growing acceptance of cannabinoid-based therapies in mainstream medicine

6Expansion of the global cannabis market

7Regulatory approvals for new cannabinoid products

8Clinical trial results impacting product efficacy and safety

My Notes

"We are positioned to capitalize on the evolving regulatory landscape and expand our market presence."

Moat: MGC Pharmaceuticals has a moderate moat due to its proprietary formulations and regulatory compliance, but faces significant competition.

growth - Investors seeking exposure to the emerging cannabis pharmaceutical market.

Higher interest rates could increase financing costs for R&D and operations, potentially impacting cash flow and valuation multiples.

Watch on earnings: Regulatory approval timelines for new products, Clinical trial success rates, Market share in the cannabinoid pharmaceuticals sector.